Performance analysis of PharmaCyte Biotech (PMCB)
Annual Return
Over the past 3 years, PMCB has had an average annual return of -38.77%, underperforming the benchmark SPY, which returned +22.45% annual.
Over the past 5 years, PMCB has had an average annual return of -48.61%, underperforming the benchmark SPY, which returned +13.88% annual.
Over the past 10 years, PMCB has had an average annual return of -39.04%, underperforming the benchmark SPY, which returned +15.45% annual.
Since Sep 17, 2010, PMCB has had an average annual return of -15.49%, underperforming the benchmark SPY, which returned +14.87% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +0.28% | -53.88% | -27.29% | -26.29% | +17.18% | -75.93% | -83.46% | +9.46% | -38.33% | -59.70% | +223.83% | -74.46% |
| 2014 | 2013 | 2012 | 2011 | 2010 | |||||||
| +76.47% | +176.42% | -18.90% | +264.01% | +89.39% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +13.14% | -15.73% | -3.70% | +8.62% | +15.58% | -12.99% | +0.28% | ||||||
| 2025 | +2.21% | +9.88% | -29.12% | -0.82% | -17.33% | +6.29% | -6.38% | -7.92% | +3.27% | -4.11% | -16.83% | -6.35% | -53.88% |
| 2024 | +1.42% | -4.11% | +12.86% | -10.57% | -7.53% | -0% | +0% | -21.92% | +24.80% | -5.25% | -5.48% | -8.19% | -27.29% |
| 2023 | -1.36% | +3.82% | -3.00% | +0.32% | +7.88% | -9.19% | -7.01% | -7.88% | -14.28% | +0.93% | +6.61% | -4.44% | -26.29% |
| 2022 | -14.40% | -0.48% | +7.97% | +1.33% | -1.32% | -2.58% | +6.67% | +10.06% | -8.75% | +22.51% | +2.71% | -2.98% | +17.18% |
| 2021 | +168.65% | +53.89% | -38.27% | +3.60% | -28.31% | -14.96% | -28.26% | -71.94% | -5.92% | -11.04% | -8.16% | -3.48% | -75.93% |
| 2020 | +48.15% | -15.00% | -41.18% | -33.33% | -3.50% | +55.44% | -53.33% | -15.00% | +42.86% | -47.65% | -33.15% | +12.61% | -83.46% |
| 2019 | +12.84% | +19.76% | -0% | -18.00% | -7.07% | +2.36% | +1.28% | -12.40% | +6.36% | -4.89% | -14.28% | +35% | +9.46% |
| 2018 | +19.83% | -16.55% | -12.00% | +2.27% | -3.89% | +31.60% | -18.01% | -6.25% | +14.29% | -13.33% | -7.24% | -23.29% | -38.33% |
| 2017 | -23.10% | -3.93% | -9.09% | -20.00% | -12.50% | -14.29% | +33.33% | -25.00% | +0% | -10.83% | -6.54% | +20% | -59.70% |
Drawdown analysis of PharmaCyte Biotech (PMCB)
The maximum drawdown for the PMCB was -99.92%, occurring on Nov 20, 2025. This drawdown has not yet recovered.
The current PMCB drawdown is -99.91%.
Since Sep 17, 2010 PMCB has experienced the following drawdowns:
- 50% or more: 6 times
- 40% or more: 6 times
- 30% or more: 6 times
- 20% or more: 8 times
- 10% or more: 12 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.92% | Feb 27, 2014 | 2946 | Nov 20, 2025 | Ongoing | Ongoing | Ongoing |
| -66.67% | Nov 2, 2010 | 31 | Dec 16, 2010 | 30 | Jan 31, 2011 | 61 |
| -66.20% | Apr 23, 2012 | 171 | Dec 27, 2012 | 60 | Mar 26, 2013 | 231 |
| -61.43% | May 17, 2011 | 193 | Feb 22, 2012 | 42 | Apr 23, 2012 | 235 |
| -53.75% | Feb 4, 2011 | 47 | Apr 13, 2011 | 20 | May 12, 2011 | 67 |
| -50.46% | May 13, 2013 | 38 | Jul 8, 2013 | 139 | Jan 27, 2014 | 177 |
| -27.78% | Sep 30, 2010 | 7 | Oct 11, 2010 | 11 | Oct 26, 2010 | 18 |
| -20.73% | Mar 27, 2013 | 8 | Apr 9, 2013 | 9 | Apr 22, 2013 | 17 |
| -19.71% | Jan 27, 2014 | 2 | Jan 29, 2014 | 15 | Feb 20, 2014 | 17 |
| -16.67% | Apr 22, 2013 | 2 | Apr 24, 2013 | 3 | Apr 29, 2013 | 5 |
| -12.50% | Sep 22, 2010 | 2 | Sep 24, 2010 | 4 | Sep 30, 2010 | 6 |
| -10.41% | Feb 24, 2014 | 1 | Feb 25, 2014 | 1 | Feb 26, 2014 | 2 |
| -5.00% | Oct 29, 2010 | 1 | Nov 1, 2010 | 1 | Nov 2, 2010 | 2 |
| -3.47% | Apr 29, 2013 | 1 | Apr 30, 2013 | 2 | May 2, 2013 | 3 |
| -1.59% | May 3, 2013 | 1 | May 6, 2013 | 1 | May 7, 2013 | 2 |